

14 Dec 2018 | Analysis

QUOTED. Dec. 14, 2018. Aaron Josephson.

by

A revised bill circulating in both the US House and Senate would revamp FDA regulation of diagnostics to create a pre-certification process to validate test developers.

"Two key features of the bill that are likely to appeal most to diagnostic companies are pre-certification and review by accredited persons (i.e., third party review), both of which have to the potential to minimize FDA review, which is considered by some to be burdensome," - Aaron Josephson, Senior Director, ML Strategies

- Find out more: ['Reined-In' US Diagnostics Legislation Adds Pre-Certification, Other Updates](#)

[Click here](#) for a free trial of *Medtech Insight*